Related Experiment Video
Updated: Jun 16, 2025
04:22
Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
790
Non-coding RNA biomarkers in Alzheimer's disease
Mozhdeh Mohammadpour1, Kholoud Saeidi2, Felora Ferdosi3
1Department of Physical Medicine and Rehabilitation, Iran University of Medical Sciences, Tehran, Iran.
Summary
Noncoding RNAs (ncRNAs) show promise as biomarkers for early Alzheimer's disease (AD) diagnosis. These molecules, including microRNAs (miRNAs), circular RNAs (circRNAs), long noncoding RNAs (lncRNAs), and PIWI-interacting RNAs (piRNAs), offer new avenues for targeted therapies.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Alzheimer's disease (AD) is a leading cause of dementia, characterized by cognitive decline and neuropathological hallmarks like amyloid-beta plaques.
- Current AD treatments offer only symptomatic relief, underscoring the need for early diagnostic biomarkers and disease-modifying therapies.
Purpose of the Study:
- To review the role of noncoding RNAs (ncRNAs) as potential biomarkers for Alzheimer's disease.
- To explore the diagnostic and therapeutic potential of various ncRNA classes in AD.
Main Methods:
- Comprehensive literature review of studies investigating ncRNA expression and function in Alzheimer's disease.
- Analysis of expression patterns, functional significance, and detection methodologies for ncRNAs in AD.
Main Results:
- Dysregulation of microRNAs (miRNAs), circular RNAs (circRNAs), long noncoding RNAs (lncRNAs), and PIWI-interacting RNAs (piRNAs is linked to AD pathology.
- These ncRNAs are implicated in key processes such as neurodegeneration, synaptic function, and amyloid precursor protein processing.
Conclusions:
- ncRNAs represent a promising class of biomarkers for early AD detection and monitoring.
- Further research into ncRNAs could lead to novel therapeutic strategies for Alzheimer's disease, moving beyond symptomatic treatment.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
02:30siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K